Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.52%
0%
1.52%
6 Months
4.55%
0%
4.55%
1 Year
-6.84%
0%
-6.84%
2 Years
-20.0%
0%
-20.0%
3 Years
2.22%
0%
2.22%
4 Years
-12.38%
0%
-12.38%
5 Years
-24.9%
0%
-24.9%
Tristel Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.96%
EBIT Growth (5y)
7.04%
EBIT to Interest (avg)
5.99
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
1.17
Tax Ratio
15.95%
Dividend Payout Ratio
102.01%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
28.29%
ROE (avg)
16.89%
Valuation key factors
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
5.50
EV to EBIT
19.70
EV to EBITDA
15.40
EV to Capital Employed
7.81
EV to Sales
3.72
PEG Ratio
2.15
Dividend Yield
381.94%
ROCE (Latest)
39.66%
ROE (Latest)
21.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Jun'23
Jun'23
Jun'22
Change(%)
Net Sales
36.00
31.10
15.76%
Operating Profit (PBDIT) excl Other Income
8.00
6.90
15.94%
Interest
0.20
0.20
Exceptional Items
-0.10
-2.50
96.00%
Consolidate Net Profit
4.50
1.00
350.00%
Operating Profit Margin (Excl OI)
150.70%
134.40%
1.63%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2023 is 15.76% vs 0.32% in Jun 2022
Consolidated Net Profit
YoY Growth in year ended Jun 2023 is 350.00% vs -72.97% in Jun 2022
About Tristel Plc 
Tristel Plc
Pharmaceuticals & Biotechnology
Tristel Plc is a United Kingdom-based manufacturer of infection prevention and contamination control products. The Company's technology is a chlorine dioxide formulation. The Company operates through three segments: Human Healthcare, Animal Healthcare and Contamination Control. The Human Healthcare segment is engaged in the manufacture, development and sale of infection control and hygiene products, which include products that are used primarily for infection control in hospitals. The segments products are marketed under the brand, Tristel. The Animal Healthcare segment relates to manufacture and sale of disinfection and cleaning products into veterinary and animal welfare sectors. The segments products are marketed under the brand, Anistel. The Contamination Control segment addresses the pharmaceutical and personal care product manufacturing industries. The segments products are marketed under the brand, Crystel. Its manufacturing facility is located in Newmarket, Cambridgeshire.
Company Coordinates 
Company Details
Lynx Business Park,Fordham Road , SNAILWELL None : CB8 7NY
Registrar Details






